Catalyst Crew Technologies Appoints Dr. Kevin Rodan Levy as CEO to Lead AI Healthcare Transformation

Catalyst Crew Technologies Corp. has announced a comprehensive leadership transition with the appointment of Dr. Kevin Rodan Levy as Chief Executive Officer, President, Chief Financial Officer, Secretary, Treasurer, and Sole Director effective February 17, 2026. This change follows the resignation of the company's prior officers and directors as disclosed in regulatory filings with the U.S. Securities and Exchange Commission. The appointments represent a strategic alignment with the company's recently announced shift toward artificial intelligence-enabled healthcare technology solutions.

Dr. Rodan brings a unique combination of clinical medical training, healthcare operations experience, and technology platform leadership to his new role. Since 2021, he has served as Chief Executive Officer of Grupo Casamed 18 C.A., where he was involved in healthcare delivery management and organizational development initiatives. He has also led EmpleUp, a technology-focused human capital and recruitment platform. This professional background positions him to guide the company's transformation into AI-driven healthcare solutions, particularly for emerging markets.

The company's strategic focus involves developing scalable platforms that address access and efficiency challenges in healthcare systems, with initial emphasis on Latin American markets. According to Dr. Rodan, the company is committed to disciplined execution of this strategic transition and building a strong operational foundation for long-term sustainable development. The company intends to pursue opportunities across telehealth infrastructure, remote patient monitoring, healthcare data analytics, and integrated digital care platforms designed to improve access, efficiency, and care coordination.

This leadership change comes as Catalyst Crew Technologies positions itself as an artificial intelligence-driven healthcare technology company focused on emerging markets. The company is actively executing its strategic transition into AI-enabled healthcare through technology development initiatives, strategic partnerships, and targeted acquisitions. For more information about the company's direction, investors can access official filings through the U.S. Securities and Exchange Commission website or visit the company's website for additional details.

The appointment of Dr. Rodan represents a significant step in the company's evolution, combining healthcare expertise with technology leadership to address growing demand for modernized healthcare delivery systems. As a development-stage enterprise that has not yet generated revenues from its new business direction, the company faces challenges including securing financing, completing acquisitions, and obtaining regulatory approvals. The company will continue providing updates through regulatory filings and public disclosures as it advances its AI healthcare initiatives in emerging markets.